Combination Drug Therapy for Obstructive and Central Sleep Apnea

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for obstructive sleep apnea (OSAS) are cumbersome, expensive, and ineffective in addressing the underlying pathophysiology, while existing pharmacological agents have not proven successful in treating both OSAS and central sleep apnea syndrome (CSAS).

Innovation Solution

A pharmacological treatment involving the co-administration of a carbonic anhydrase inhibitor, such as topiramate, with an aldosterone antagonist, such as spironolactone, to address metabolic acidosis and promote breathing, potentially alleviating sleep apnea symptoms and reducing the need for high dosages of either agent alone.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current standard treatments (CPAP, surgery, intraoral devices) are used for OSAS, then breathing support is provided, but the treatments are cumbersome, expensive, and do not address underlying pathophysiology

Engineering Contradiction:

Improveeffectiveness in addressing pathophysiologyVSAvoidcumbersome nature of treatment

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent replaces mechanical treatment systems (CPAP machines, surgical interventions, intraoral devices) with a pharmacological system using carbonic anhydrase inhibitors and aldosterone antagonists. This substitution addresses the underlying metabolic acidosis and aldosterone-mediated pathways that contribute to sleep apnea pathophysiology, eliminating the need for cumbersome mechanical equipment while targeting the root causes of the disorder.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If high dosages of single pharmacological agents are used, then treatment effect is achieved, but side effects increase and effectiveness is limited

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent combines two pharmacological agents with different mechanisms of action: carbonic anhydrase inhibitors (addressing metabolic acidosis) and aldosterone antagonists (addressing aldosterone-mediated pathways). This combination therapy achieves synergistic effects where each agent contributes to treating sleep apnea through distinct physiological pathways, allowing for reduced dosages of each individual agent while minimizing side effects and improving overall treatment effectiveness.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent changes the therapeutic parameters by introducing a dual-agent regimen that targets multiple pathophysiological parameters simultaneously (metabolic acidosis and aldosterone levels). This multi-parameter approach allows for more precise control of treatment effects and reduces the need for high dosages of single agents, thereby decreasing harmful side effects while maintaining or improving treatment effectiveness.

Inventive Principle:

Principle #35Parameter changes

3Adaptability or versatility

If existing pharmacological agents are used for both OSAS and CSAS, then treatment is simplified, but no agent has proved successful in treating both conditions

Engineering Contradiction:

Improveability to treat both OSAS and CSASVSAvoidproven success in treatment

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent develops a universal pharmacological treatment system that can address both obstructive sleep apnea syndrome and central sleep apnea syndrome through a single combination regimen. The carbonic anhydrase inhibitor component addresses metabolic acidosis relevant to both conditions, while the aldosterone antagonist component targets aldosterone-mediated pathways that contribute to both OSAS and CSAS pathophysiology, providing a versatile treatment approach that has not been achieved by existing single agents.

Inventive Principle:

Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The combination therapy effectively reduces the frequency and severity of apneas and hypopneas, offering a simpler and more effective treatment for both OSAS and CSAS by minimizing side effects and dosage requirements.

Implementation Method 1

a carbonic anhydrase inhibitor, such as topiramate

Methodology Applied

Scientific EffectCarbonic anhydrase inhibition: Enzyme

Implementation Method 2

an aldosterone antagonist, such as spironolactone

Methodology Applied

Scientific EffectAldosterone antagonism:

Data Source

PatentUS20260027139A1Treatment of sleep apnea with a combination of a carbonic anhydrase inhibitor and an aldosterone antagonist

Publication Date: 2026.01.29 VIVUS LLC

AI summary

This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from sleep apnea, including obstructive sleep apnea syndrome (OSAS). Treatment is effected by administering a carbonic anhydrase inhibitor to the patient in combination with an aldosterone antagonist. Formulations containing a therapeutically effective amount of a carbonic anhydrase inhibitor and a therapeutically effective amount of an aldosterone antagonist are provided as well.